Etienna Bio

What Etienna Bio does

Etienna Bio, Inc. is a privately held, pre-commercial regenerative biotechnology company founded in 2025 and headquartered in Leawood, Kansas. The company is developing a single autologous adipose-derived cell platform that combines patient-harvested adipose-derived progenitor cells expanded more than 1,000-fold with a proprietary adipose-derived hydrogel matrix (thermosensitive scaffold). Expanded cells are differentiated into either adipocytes for fat-tissue applications or collagen-producing fibroblasts for dermal rejuvenation, then delivered via the biodegradable scaffold to enable vascularization and tissue integration.

The platform is being applied to four aesthetic and reconstructive indications: breast reconstruction, breast augmentation, fat transfer, and collagen-based dermal fillers. The company targets the $17.4B aesthetic market, positioning its autologous, non-gene-modified, non-drug approach against synthetic fillers (which fade), implants (which fail), and conventional fat grafting (which has unpredictable 30–70% reabsorption). The underlying technology is held under an exclusive worldwide license from UMass Chan Medical School, with scientific guidance from SAB members Dr. Silvia Corvera and Dr. Michael P. Czech.

Etienna Bio plans to generate revenue through direct commercialization of cell therapy products and procedures sold to aesthetic clinics, plastic surgery practices, and dermatology providers via enterprise field sales, with potential additional upside from platform licensing. The go-to-market is staged: the company is currently pre-revenue, with pricing, contracts, and customer relationships not yet disclosed. Leadership comprises co-founders Janet DeLeon (President & CEO), Dr. Missy Clifton (CMO), Robert Lewis (Chairman), and Tim Dugan (CCO), bringing a claimed combined track record of 100+ FDA approvals across regulatory, clinical, and product development disciplines.

Name

Etienna Bio

Legal name

Etienna Bio, Inc.

Website

https://etiennabio.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

1–10 employees

Short description

Etienna Bio is a pre-commercial regenerative biotech developing an autologous adipose-derived cell platform—combining 1,000-fold expanded patient progenitor cells with a proprietary hydrogel scaffold—for breast augmentation, breast reconstruction, fat transfer, and dermal filler applications targeting the $17.4B aesthetic market.

Ownership category

akta.pro rank

Product category

Autologous Cell Therapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)

akta.pro secondary industries

Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG), Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)

Keywords

• Autologous cell therapy
• Regenerative medicine
• Aesthetic biotechnology
• Tissue engineering
• Adipose derived cells

Headquarters

HQ city

Leawood

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Autologous Cell Therapy Products: Etienna Bio plans to commercialize cell-enabled regenerative and aesthetic products including breast augmentation, reconstruction, fat transfer, and collagen fillers. The company will generate revenue through the sale of cell therapy products and procedures to healthcare providers and aesthetic clinics. As a regenerative medicine company, revenue will come from product sales and potentially procedure-based pricing.
2. Platform Licensing and Commercialization: With exclusive worldwide rights to the licensed UMass Chan technology, Etienna Bio can develop, manufacture, and commercialize licensed products. Revenue generation approach includes direct commercialization of aesthetic products in the $17.4B aesthetic market.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Etienna Bio develops an autologous adipose-derived cell therapy platform that expands a patient's own fat-derived progenitor cells by more than 1,000-fold and differentiates them into adipocytes or collagen-producing fibroblasts for delivery via a proprietary thermosensitive hydrogel scaffold. The platform is being commercialized across four aesthetic indications: breast augmentation, breast reconstruction, fat transfer, and collagen-based dermal fillers. The company holds an exclusive worldwide license to the underlying UMass Chan technology.

Product overview

Etienna Bio is a regenerative biotechnology company developing a single autologous adipose-derived cell platform combined with a proprietary adipose-derived hydrogel matrix (thermosensitive scaffold). The platform uses a patient's own cells harvested in a minimally invasive outpatient procedure, expanded 1,000-fold, and differentiated into adipocytes or collagen-producing fibroblasts for delivery via biodegradable scaffold. The company is advancing four key applications: breast reconstruction, breast augmentation, fat transfer, and collagen dermal fillers—all utilizing the same underlying platform technology to address the $17.4 billion aesthetic market.

Differentiator

Problem solved

Functional benefit

Products and services

• Autologous Adipose-Derived Cell Platform Proprietary biotechnology platform combining human adipose-derived progenitor cells with an adipose-derived hydrogel matrix for cell-enabled regenerative and aesthetic applications. Enables 1,000-fold expansion of patient cells and differentiation into adipocytes or collagen-producing fibroblasts for therapeutic use.
• Breast Reconstruction Therapy Autologous cell therapy application for breast reconstruction to restore tissue lost due to mastectomy or trauma using the patient's own expanded cells delivered through the proprietary hydrogel scaffold.
• Breast Augmentation Therapy Natural breast augmentation using expanded autologous adipose-derived cells to achieve volume without synthetic implants, leveraging the patient's own biology for permanent tissue integration.
• Fat Transfer Therapy Cell-enabled fat transfer procedure using expanded autologous cells for improved fat survival and predictability compared to traditional fat grafting, which suffers from 30–70% reabsorption rates.
• Collagen Dermal Filler Collagen-producing fibroblast-based dermal filler application using the patient's own expanded cells for natural facial rejuvenation, designed as an alternative to synthetic hyaluronic acid fillers.

Quantifiable outcome

• 1,000X cell expansion from small fat sample
• +2 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• UMass Chan Medical SchoolcoreOEM/ Whitelabel/ Licensing Partner · 9 January 2026Etienna Bio entered into an exclusive, worldwide license agreement with UMass Chan Medical School to develop and commercialize a proprietary adipose-derived cellular and matrix technology platform. The licensed technology is based on foundational research into human adipose tissue progenitors and adipose-derived hydrogel compositions. UMass Chan retains rights for academic research and non-commercial use while Etienna Bio obtained exclusive global rights to develop, manufacture, and commercialize licensed products for regenerative and aesthetic applications.

Scale indicators3 records

Recent moves4 records

Expansion highlights5 records

Broad incumbents

• InMode: InMode is an established aesthetic medical device company offering energy-based solutions for body contouring, skin tightening, and facial rejuvenation. Comparable as a major player in the same $17.4B aesthetic market that Etienna Bio targets, though InMode uses device-based rather than cell-based approaches.
• Galderma: Galderma is one of the world's largest pure-play dermatology and aesthetics companies, with leading injectable fillers (Restylane, Sculptra) and a major presence in breast aesthetics. Comparable as the dominant incumbent whose synthetic fillers Etienna Bio's autologous platform aims to disrupt.
• AbbVie (Allergan Aesthetics): AbbVie's Allergan Aesthetics division markets Botox, the Juvederm filler family, and breast implants (Natrelle)—dominant products across all four aesthetic indications Etienna Bio targets. Comparable as the largest incumbent whose products and physician relationships Etienna Bio must displace.
• Evolus: Evolus is an aesthetics company commercializing neurotoxins (Jeuveau) and expanding into dermal fillers and biostimulators. Comparable as a focused aesthetics company competing in the same physician-administered injectable market that Etienna Bio's collagen filler application would enter.
• Revance Therapeutics: Revance develops and commercializes aesthetic injectables including the RHA filler collection and DaxibotulinumtoxinA (Daxxify). Comparable as an aesthetics-focused company selling premium dermal fillers into the same physician channels Etienna Bio plans to target.

Direct peers

• Cytori Therapeutics: Cytori Therapeutics developed autologous adipose-derived cell therapies (Celution system) for regenerative medicine applications including aesthetics and wound healing. Closely comparable historical direct competitor in autologous adipose-derived cell processing for aesthetic indications.
• Lipogems: Lipogems develops and commercializes an autologous adipose-derived cell processing system for orthopedic and aesthetic indications. Directly comparable to Etienna Bio as both use a patient's own fat-derived cells to create regenerative therapies, though Lipogems focuses on mechanical processing rather than 1,000X expansion.
• GID Group: GID Group develops autologous cell therapy platforms using adipose-derived stem cells for hair restoration, orthopedics, and aesthetics. Closely comparable to Etienna Bio in technology approach (autologous adipose-derived SVF cells) and target indications including aesthetic rejuvenation.
• Healeon Medical: Healeon Medical develops autologous fat processing and cell-enrichment technologies for aesthetic and reconstructive procedures. Comparable to Etienna Bio in targeting plastic surgeons and aesthetic practices with cell-enabled fat transfer and tissue regeneration solutions.

Emerging players

• Establishment Labs: Establishment Labs develops Motiva breast implants and is exploring tissue-based breast augmentation alternatives. Comparable as a direct competitor in the breast augmentation and reconstruction segment Etienna Bio targets, with overlapping customer base of plastic surgeons.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks4 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/etienna-bio

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Etienna Bio